Call centre software producer Replicant closed a $78m series B round backed by Salesforce Ventures while Ashvattha Therapeutics raised $69m from investors including strategic partner Huadong Medicine.

Funding

Replicant, a US-based provider of contact centre automation software, completed a $78m series B round on Tuesday featuring Salesforce Ventures, the corporate venture capital arm of enterprise software producer Salesforce. Growth equity firm Stripes led the round, which included IronGrey, Omega Venture Partners, Norwest Venture Partners and Replicant’s founding investor, venture studio Atomic.

Pharmaceutical company Huadong Medicine led US-based hydroxyl dendrime drug developer Ashvattha Therapeutics’ $69m series B round yesterday through its Huadong Medicine Investment Holding vehicle. The corporate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn